We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Horizon Therapeutics Public Limited Company | NASDAQ:HZNP | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 116.30 | 116.31 | 116.30 | 0 | 01:00:00 |
The restricted stock unit vests over four years, with 25 percent of the shares vesting on each anniversary of the applicable vesting commencement date, subject to the new employee's continued service relationship with the Company. The restricted stock unit also is subject to the terms and conditions of the Company's 2014 Equity Incentive Plan and the restricted stock unit agreement pursuant to which the restricted stock unit was granted.
The stock option has an exercise price per share equal to $14.05, the fair market value on the grant date, and vests over four years, with 25 percent of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereafter, subject to the new employee's continued service relationship with the Company. The stock option also has a 10-year term and is subject to the terms and conditions of the Company's 2014 Equity Incentive Plan and the stock option agreement pursuant to which the option was granted.
The restricted stock unit and stock option were granted as inducements material to Ms. Konstantinovsky entering into employment with Horizon Pharma on Sept. 11, 2017 in accordance with NASDAQ Listing Rule 5635(c)(4).
About Horizon Pharma plcHorizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets 11 medicines through its orphan, rheumatology and primary care business units. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.
Contacts:Tina VenturaSenior Vice President, Investor RelationsInvestor-relations@horizonpharma.com
Ruth VenningExecutive Director, Investor RelationsInvestor-relations@horizonpharma.com
U.S. Media Contact:Geoffrey CurtisSenior Vice President, Corporate Affairs and Chief Communications Officermedia@horizonpharma.com
Ireland Media Contact: Ray Gordon Gordon MRM ray@gordonmrm.ie
1 Year Horizon Therapeutics Pub... Chart |
1 Month Horizon Therapeutics Pub... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions